AnaptysBio (ANABV) Stock Analysis

What AnaptysBio does

AnaptysBio, Inc. operates as a clinical-stage biotechnology firm, primarily focused on the development of novel antibody product candidates. Its pipeline prominently features therapeutic agents such as ANB030 and Imsidolimab. The company also utilizes a proprietary SHM platform, which biologically replicates the human immune system's natural process of somatic hypermutation. This advanced technology allows for the rapid in vitro generation of a diverse array of therapeutic-grade antibodies. Established in November 2005 by founders Andrew B. Cubitt, William J. Boyle, Kevin J. Kinsella, and Nicholas B. Lydon, AnaptysBio maintains its headquarters in San Diego, California.

Key metrics

ETFs linked to ANABV

Broad-market and Healthcare sector ETFs an investor holding AnaptysBio is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how ANABV fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for AnaptysBio?

AnaptysBio trades under the ticker ANABV on NASDAQ.

Which exchange is ANABV listed on?

ANABV is listed on NASDAQ.

What sector does AnaptysBio operate in?

AnaptysBio is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze ANABV in a portfolio?

PortView shows ANABV's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.